



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLÓGIA

ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



CASE AND RESEARCH LETTER

Sentinel Lymph Node Biopsy in Elderly Melanoma Patients: A Real Practice Cohort



Biopsia del ganglio centinela en pacientes mayores con melanoma: cohorte en la práctica real

To the Editor:

Melanomas in the elderly account for 40% of diagnosed melanomas and account for 60.2% of deaths.¹ Sentinel lymph node biopsy (SLNB) is currently recommended as a staging method for intermediate-thickness melanoma (Breslow thickness, ≥ 0.8 mm). The ASCO guidelines state that SLNB may be recommended at all ages after discussion of the potential benefits and risks of harm.²

Data from the Surveillance, Epidemiology and End Results Program (SEER) suggest that the incidence of thick melanoma is significantly higher in patients over 60 years of age and that mortality is higher than in other age groups. The age group with the highest percentage of death from melanoma is patients aged 75–84 years. In addition, a study analysing 3 different cohorts – including the SEER cohort – with more than 300,000 patients found that age predicts a worse melanoma-specific survival.^{3,4} SLNB remains controversial and the peculiarities in the elderly have not been thoroughly studied.

The primary objective of our study was to determine if there is a difference in SLNB status predictors in two different age groups, younger and older than 75 years old. A secondary objective was to describe the difference in complications in both groups.

A cohort, retrospective, single centre, longitudinal, observational study was performed with all the patients that have undergone SNLB from January 2008 to December 2020. Inclusion criteria were the following: All consecutive adult patients with cutaneous melanoma that underwent SLNB. The cohort was divided in two age groups for age related analysis, younger and older than 75 years old. The study protocol was approved by institutional review board and informed consent was obtained from all patients.

The following clinical and histologic characteristics were selected as independent variables: sex, age, anatomic

location, histologic subtype, Breslow thickness, ulceration, regression, lymphovascular invasion, mitosis, SLNB location, and SLNB complications.

Statistical analyses were performed using SPSS software ver. 22.0 (IBM®, Armonk, NY, USA). Group comparisons were performed using the Fisher test or Mann–Whitney *U*-test, Pearson chi-square test or independent samples *T* test as necessary. Multivariate logistic regression analysis with backward stepwise selection was performed to assess associations ($p < 0.1$).

Patient characteristics are summarized in [Table 1](#). The sample includes a total of 150 patients who have undergone SLNB. The SLNB was identified in 146 patients (97.3%). The mean age of the participants was 70.6 years old. Positive SLNB was more frequent in ≥ 75 -year-old group (29.3% vs. 18.3%). Although this result was not statistically significant ($p = 0.114$).

Bivariate and multivariate analysis are summarized in [Tables 2 and 3](#). The logistic regression multivariate analysis showed that for the ≥ 75 -year-old group, ulceration was associated with SNLB positivity with an Odds Ratio of 13.3 (95%CI 2.7–65.0). Also, the risk grows when age increases, specifically the odds increase by 19% for each year over 82-year-old on the stepwise selection model. As secondary objective regarding complications, 86% of the patients did not experience any, and seroma, affecting 9.6% of the patients was the commonest with no difference among both age groups.

Many reports have found age-dependent prognostic factors on SLNB status but most randomized trials and major studies have excluded patients older than 70–75 years.^{5,6} Consequently, data on the feasibility and diagnostic accuracy of the method in this patient group are so far lacking. Also, there are some existing models to predict SN status in melanoma patients that combine clinicopathologic factors depending on the primary tumour, but they do not take age into account or are not specific for the elderly.⁷ It has been postulated that SLNB is a poor predictor of prognosis in older patients because its positivity declines with increasing age.⁸ In a large study ($n = 858$), the frequency of sentinel node (SN) metastases decreased with increasing age from 18 to 70 years, despite an increase in other poor prognostic factors. Whether this represents a lower sensitivity of the procedure or a different biological behaviour of melanomas in older patients remains unanswered.⁹ In our cohort, posi-

<https://doi.org/10.1016/j.ad.2022.05.043>

0001-7310/© 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1 Clinical and histopathological characteristic of study patients.

Variable	Cohort		<75 years-old		≥75 years-old		p
	N	%	N	%	N	%	
<i>Sex</i>							
Male	85	56.7	40	53.3	45	60	0.410
Female	65	43.3	35	46.7	30	40	
<i>Location</i>							
Trunk	61	40.7	28	37.3	33	44	0.337
Head and neck	18	12	10	13.3	8	10.7	
Upper limb	30	20	19	25.3	11	14.7	
Lower limb	41	27.3	18	24	23	30.7	
<i>Histologic subtype</i>							
<i>Lentigo maligno</i>	5	3.5	0	0	5	6.9	0.006
Superficial spreading melanoma	76	53.5	40	57.1	36	50	
Nodular melanoma	5	3.5	5	7.1	0	0	
Acral lentiginous melanoma	8	5.6	6	8.6	2	2.8	
Other	48	33.8	19	27.1	29	40.3	
<i>Lymphovascular invasion</i>							
Absent	147	98.7	74	98.7	73	98.6	1.000
Present	2	1.3	1	1.3	1	1.4	
<i>Ulceration</i>							
Absent	119	79.3	57	76	62	82.7	0.313
Present	31	20.7	18	24	13	17.3	
<i>Regression</i>							
Absent	144	96	72	96	72	96	1.000
Present	6	4	3	4	3	4	
<i>SLNB location</i>							
Axillar	73	50.7	36	52.2	37	49.3	0.753
Cervical	13	9	6	8.7	7	9.3	
Inguinal	52	36.1	23	33.3	29	38.7	
Other	6	4.2	4	5.8	2	2.7	
<i>SLNB result</i>							
Negative	111	76	58	81.7	53	70.7	0.119
Positive	35	24	13	18.3	22	29.3	
<i>Lymphadenectomy result</i>							
Negative	21	63.6	10	71.4	11	57.9	0.424
Positive	12	36.4	4	28.6	8	42.1	
<i>Nodal metastases on follow-up</i>							
Absent	127	84.7	69	92	58	77.3	0.013
Present	23	15.3	6	8	17	22.7	
<i>Visceral metastases on follow-up</i>							
Absent	132	88	69	92	63	84	0.132
Present	18	12	6	8	12	16	
<i>Complications SLNB</i>							
No	129	86	64	85.3	65	86.7	0.201
Seroma	14	9.3	6	8	8	10.7	
Paresthesia	3	2	1	1.3	2	2.7	
SLNB not found	4	2.7	4	5.3	0	0	
<i>Desenlace complicación BSGC</i>							
Complete remission	16	94.1	7	100	9	90	1.000
Persistence	1	5.9	0	0	1	10	

Table 1 (Continued)

Variable	Cohort		<75 years-old		≥75 years-old		p
	N	%	N	%	N	%	
<i>Exitus</i>							
No	133	88.7	70	93.3	63	84	0.071
Yes	17	11.3	5	6.7	12	16	
	Mean	St. dev.	Mean	St. dev.	Mean	St. dev.	p
Age	70.6	15.9	58.4	13.2	82.8	5.6	(<0.001)
Breslow index	2.6	2.1	2.6	2.1	2.6	2.0	0.914
Mitosis	3.8	6.1	4.0	5.7	3.6	6.4	0.707

SLNB: sentinel node biopsy, St. dev: standard deviation.

Table 2 Superior: Bivariate studies between study category and outcome using χ^2 , Fisher, Mann–Whitney *U* or independent samples *T* test as necessary.

Variable	<75yo				p	≥75yo				p
	–SLNB		+SLNB			–SLNB		+SLNB		
	N	%	N	%		N	%	N	%	
<i>Sex</i>										
Male	30	51.7%	7	53.8%	0.89	33	62.3%	12	54.5%	0.534
Female	28	48.3%	6	46.2%		20	37.7%	10	45.5%	
Si	1	1.7%	1	7.7%		2	3.8%	0	0%	
<i>Location</i>										
Trunk	23	39.7%	3	23.1%	0.725	25	47.2%	8	36.4%	0.102
Head and neck	6	10.3%	2	15.4%		8	15.1%	0	0%	
Upper limb	15	25.9%	4	30.8%		7	13.2%	4	18.2%	
Lower limb	14	24.1%	4	30.8%		13	24.5%	10	45.5%	
<i>Histologic subtype</i>										
<i>Lentigo maligno</i>	32	59.3%	5	41.7%	0.642	5	9.6%	0	0%	0.002
Superficial spreading melanoma	4	7.4%	1	8.3%		31	59.6%	5	25.00%	
Nodular melanoma	5	9.3%	1	8.3%		2	3.8%	0	0%	
Acral lentiginous melanoma	13	24.1%	5	41.7%		14	26.9%	15	75.00%	
<i>Lymphovascular invasion</i>										
Absent	57	98.3%	13	100.00%	1	52	98.1%	21	100.00%	1
Present	1	1.7%	0	0%		1	1.9%	0	0%	
<i>Ulceration</i>										
Absent	45	77.6%	9	69.2%	0.496	49	92.5%	13	59.1%	0.001
Present	13	22.4%	4	30.8%		4	7.5%	9	40.9%	
<i>Regression</i>										
Absent	55	94.8%	13	100.00%	1	51	96.2%	21	95.5%	1
Present	3	5.2%	0	0%		2	3.8%	1	4.5%	
<i>SLNB location</i>										
Axillar	30	53.6%	6	46.2%	0.574	28	52.8%	9	40.9%	0.056
Cervical	4	7.1%	2	15.4%		7	13.2%	0	0%	
Inguinal	18	32.1%	5	38.5%		16	30.2%	13	59.1%	
Other	4	7.1%	0	0%		2	3.8%	0	0%	
<i>Lymphadenectomy result</i>										
Negative	3	60.00%	7	77.8%	0.58	0	0%	11	57.9%	–
Positive	2	40.00%	2	22.2%		0	0%	8	42.1%	

Table 2 (Continued)

Variable	<75yo				p	≥75yo				p
	-SLNB		+SLNB			-SLNB		+SLNB		
	N	%	N	%		N	%	N	%	
<i>Exitus due to melanoma</i>										
Si	4	100%	1	100%	-	6	100%	6	100%	-
<i>SNLB complication</i>										
No	53	91.4%	11	84.6%	0.553	44	83.00%	21	95.5%	0.333
Seroma	4	6.9%	2	15.4%		7	13.2%	1	4.5%	
Paraesthesia	1	1.7%	0	0%		2	3.8%	0	0%	
<i>Complication outcome</i>										
Complete remission	5	100%	2	100%	-	8	88.9%	1	100.00%	1

Variable	-SNLB			+SNLB			t	p
	N	Media	DT	N	Media	DT		
Age	53	81.55	4.66	22	85.86	6.61	-2.788	0.009
Breslow index	52	2.25	1.98	20	3.37	1.98	-2.148	0.035
Mitosis	53	3.19	5.74	22	4.50	7.89	-0.804	0.424

SLNB: sentinel node biopsy. Inferior: Bivariate studies between study category and outcome using independent samples *T* test for quantitative variables in the ≥75 year old group. The *p* values <0.1 were considered statistically significant and become part of the logistic regression model.

Table 3 Logistic regression model the behaviour of the variables is studied using a backward stepwise selection model. The variables selected to perform the study are chosen among the ones that showed statistical significance on the regression model.

	Variable forced introduction						Backward stepwise selection					
	B	ET(B)	Sig.	OR	CI95%		B	ET(B)	Sig.	OR	CI95%	
					Inferior	Superior					Inferior	Superior
Ulceration	1.046	1.139	0.359	2.846	0.305	26.556	1.945	0.869	0.025	6.997	1.275	38.404
Age ≥ 82	.277	0.092	0.003	1.32	1.101	1.581	1.418	0.801	0.077	4.127	0.859	1.834

Includes all variables that *p* < 0.1 on bivariate analysis. $\chi^2 = 24.41$; *gl* = 3; *p* ≤ 0.001; $R^2_L = 0.287$; $R^2_{Cox\&Snell} = 0.288$; $R^2_{Nagalkerke} = 0.415$.

tivity was 11 points higher in the ≥75-year-old group (29.3% vs 18.3%).

Patients in the ≥75-year-old group, with ulcerated melanoma, older than 82 years-old have the higher likelihood of positivity in SLNB in our cohort. The present study focuses on elderly patients aged 75 years or older. As it is retrospective, bias may exist. The study confirms that SLNB might be recommended in the elder safely. Although SLNB remains controversial due to its lack of impact on survival, it is still the best staging system for micrometastases. It is the authors opinion that it should be offered in elderly patients.

Conflict of interest

The authors declare they have no conflict of interest.

Acknowledgment

The authors are grateful to AM for the statistics and MGG for the correction of English language.

References

- Iglesias-Pena N, Paradelo S, Tejera-Vaquero A, Boada A, Fonseca E. Cutaneous melanoma in the elderly: review of a growing problem. *Actas Dermosifiliogr.* 2019;110:434–47, <http://dx.doi.org/10.1016/j.ad.2018.11.009>.
- Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical Oncology and society of surgical Oncology clinical practice guideline update. *J Clin Oncol.* 2018;36:399–413.

3. Surveillance, Epidemiology, and End Results (SEER). Program Cancer Statistics Review, 1975–2015, National Cancer Institute [online]. Melanoma of the skin – Cancer Stat Fact [visited 16.9.21]. doi:10.1083/jcb.144.6.1219.
 4. Weiss SA, Han J, Darvishian F, Tcheck J, Han SW, Malecek K, et al. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. *J Transl Med.* 2016;14.
 5. Chao C, Martin RC II, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, et al. Correlation between prognostic factors and increasing age in melanoma. *Ann Surg Oncol.* 2004;11:259–64.
 6. Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). *Ann Surg Oncol.* 2020;27:15–21.
 7. Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, et al. A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. *J Surg Oncol.* 2018;118:922–7.
 8. Kanzler MH. Sentinel node biopsy and standard of care for melanoma: a re-evaluation of the evidence. *J Am Acad Dermatol.* 2010;62:880–4.
 9. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, et al. Age-related lymphatic dysfunction in melanoma patients. *Ann Surg Oncol.* 2009;16:1548–52.
- P. Rodríguez-Jiménez^{a,b,*}, A. Reymundo-Jiménez^{a,b}, Y. Delgado-Jiménez^{a,b}, E. Gallo^{a,b}, R. Navarro^{a,b}, E. Vargas^{a,b}, V. Castillo^c, I. Hernández^c, E. Torres^d, F. Rodríguez-Campo^e, A. Tejera-Vaquerizo^f
- ^a *Department of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain*
^b *Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Madrid, Spain*
^c *Department of Nuclear Medicine, Hospital Universitario de La Princesa, Madrid, Spain*
^d *Department of General Surgery, Hospital Universitario de La Princesa, Madrid, Spain*
^e *Department of Oral and Maxillofacial Surgery, Hospital Universitario de La Princesa, Madrid, Spain*
^f *Instituto Globalderm, Palma del Río, Córdoba, Spain*
- * Corresponding author.
E-mail address: pedro.rodriguez.jimenez90@gmail.com (P. Rodríguez-Jiménez).